{"entity":{"id":"jecho","kind":"company","name":"Jecho","aka":["Jecho Laboratories; Jecho Biopharmaceuticals"],"tldr":"Jecho is a drug developer working in the US and China whose cancer programmes include a virus-based treatment injected into recurrent brain tumours and a medicine for early bladder cancer. It also makes other biological medicines.","summary":"Jecho, whose website is published by Jecho Laboratories, Inc. and lists sites in Frederick, Maryland, Shanghai and Tianjin, was founded in 2013, according to the company, and describes three R&D centres, a preclinical animal facility and a pilot and manufacturing base, with a portfolio spanning monoclonal and bispecific antibodies, antibody-drug conjugates, antibody radionuclide conjugates, fusion proteins, immunotoxins and oncolytic viruses. Its Chinese company Jecho Biopharmaceuticals Co., Ltd. sponsors the registry trials: JL15003, given by a single intratumoural injection with viral shedding measured, completed a phase 1 study in recurrent glioblastoma (NCT07497373) and is in a phase 1b/2 trial (NCT07501559); JL19001 is in a phase 1/2 trial alone or with BCG in high-risk non-muscle invasive bladder cancer (NCT07483970) and a phase 1 trial in advanced solid tumours or relapsed B-cell non-Hodgkin lymphoma (NCT07603479); and JLM019, given intravenously, is in a phase 1 trial in advanced solid tumours and lymphoma (NCT07623850). The sponsor also ran a phase 3 comparison of JL14002 with Lucentis in wet age-related macular degeneration (NCT07389577), which was not a cancer study. Its first registered cancer trial, NCT07483970, was posted on ClinicalTrials.gov in March 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.jechobio.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of JL15003 in recurrent glioblastoma (NCT07497373)","url":"https://clinicaltrials.gov/study/NCT07497373"},{"label":"ClinicalTrials.gov: phase 1/2 trial of JL19001 in high-risk NMIBC (NCT07483970)","url":"https://clinicaltrials.gov/study/NCT07483970"},{"label":"ClinicalTrials.gov: phase 1 trial of JL19001 in solid tumours and B-cell NHL (NCT07603479)","url":"https://clinicaltrials.gov/study/NCT07603479"},{"label":"ClinicalTrials.gov: phase 1 trial of JLM019 (NCT07623850)","url":"https://clinicaltrials.gov/study/NCT07623850"}],"tags":[],"related":[],"cancers":["glioblastoma","non-muscle-invasive-bladder-cancer","non-hodgkin-lymphoma"],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07501559"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year from the company website ('Founded in 2013'), read on 29 October 2026; the pipeline page did not render, so the mechanisms and targets of JL15003, JL19001 and JLM019 are not confirmed. JL15003 is inferred to be an oncolytic virus from the registry's measurement of viral shedding.","Headquarters is uncertain: the website lists Frederick, Maryland first, but every trial is sponsored by the Chinese company and run in China. The relationship between Jecho Laboratories, Inc. and Jecho Biopharmaceuticals Co., Ltd. was not confirmed from a filing.","The first-ever registry record for this sponsor, NCT07389577, is an ophthalmology study; the earliest cancer study is used above.","Stage is approximate."],"hq":"Frederick, MD","country":"US","companyType":"biotech","website":"https://www.jechobio.com/","founded":2013,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/jecho/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"trial":[{"id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/"}]}}